Service de biochimie clinique
Service de biochimie clinique
Manceau H.,Service de Biochimie Clinique |
Chicha-Cattoir V.,CH R Bisson |
Puy H.,APHP |
Puy H.,University Paris Diderot |
And 2 more authors.
Clinical Chemistry and Laboratory Medicine | Year: 2017
Inflammatory bowel diseases (IBDs) are chronic diseases that result from the inflammation of the intestinal wall, suspected in any patient presenting with intestinal symptoms. Until recently, the diagnosis was mainly based on both clinical and endoscopic arguments. The use of an easy, fast, reliable, non-invasive, and inexpensive biological assay is mandatory not only in diagnosis but also in evolutionary and therapeutic monitoring. To date, the fecal calprotectin is the most documented in this perspective. This marker allows the discrimination between functional and organic bowel processes with good performance. The determination of the fecal calprotectin level contributes to the evaluation of the degree of disease activity and to monitoring of therapeutic response. © 2017 Walter de Gruyter GmbH, Berlin/Boston.
Vinay P.,Service des soins palliatifs |
Comtois R.,Service dendocrinologie |
Petitclerc C.,Service de biochimie clinique |
Pavlov I.,Medecine familiale |
And 2 more authors.
Medecine Palliative | Year: 2012
Patients in their last months or weeks of life demonstrate an hypothyroid syndrome. This is due to a low secretion of TRH and TSH (central inhibition of thyroid function) as well as to a reduced transformation of T4 into T3 by desiodination in the liver and other peripheral tissues. These changes have a profound influence on the metabolism and contribute to the clinical picture observed. This is thought to be a normal adaptative phenomenon. It is believed that it protects the patients against the proteolytic effect of T3, sparing the muscle mass. Others show that the low T3 syndrome shortens the survival time in certain diseases. Our analysis suggests that thyroid replacement could be safely reduced in the end-of-life period in patients using exogenous replacement of T4. © 2011 Elsevier Masson SAS.
Measurement of glycated haemoglobin in a Tunisian population: Reference values in healthy adults and correlation with fasting blood glucose in diabetic patients [Dosage de lhémoglobine glyquée dans une population tunisienne: valeurs de référence chez les non diabétiques et corrélations avec les glycémies à jeun chez les diabétiques]
Bouzid K.,Service de biochimie clinique |
Bahlous A.,Service de biochimie clinique |
Hamdane Y.,Service de biochimie clinique |
Chelbi A.,Service de biochimie clinique |
And 4 more authors.
Immuno-Analyse et Biologie Specialisee | Year: 2011
Studies hold a debate on use of glycated haemoglobin (HbA1c) as diabetes screening method. Aim: Establish HbA1c level in healthy Tunisians and find a correlation between HbA1c and fasting blood glucose (FBG) in diabetics. Patients and methods: All the 289 healthy people benefit from FBG, 75 g oral glucose tolerance test (OGTT) and HbA1c. For the 853 diabetic patients, we collected level of FBG and HbA1c. Results: In healthy people, FBG average = 5.19 mmol/L (3.86-6.09); HbA1c = 5.83 ± 0.45% (3.75-6.50). HbA1c increased by age but was correlated with FBG. Reference intervals of HbA1c were established: six groups from (20-30 years) until (over 70 years) with an increased HbA1c level respectively from 5.46 till 5.94%. For both healthy and diabetics, there was no statistical difference between sexes. In diabetics, 1% change in HbA1c corresponded to 18 mg/dL change in FBG. Conclusion: It is important for clinicians to know reference intervals in order to screen diabetes when FBG is normal. The G0/HbA1c correlation might be clinically useful to achieve good diabetic control. La connaissance des valeurs usuelles de l'hémoglobine glyquée (HbA1c) en fonction de l'âge permettrait le dépistage du diabète chez le sujet normal. But de l'étude: Établir les valeurs de référence de l'HbA1c chez le tunisien non diabétique et rechercher une corrélation entre HbA1c et glycémie à jeun (G0) chez les diabétiques. Patients et méthodes: Les 289 témoins ont bénéficié de: G0, hyperglycémie provoquée orale (HGPO75) et HbA1c. Six groupes étaient définis de l'intervalle (20-30 ans) à (plus de 70 ans); les 853 diabétiques ont bénéficié de G0 et HbA1c. Résultats: Chez les témoins, G0 était de 5,19 mmol/L (3,86-6,09); l'HbA1c est égale à 5,83 ± 0,45 % (3,75-6,50) L'HbA1c augmentait avec l'âge mais restait corrélée à G0 L'HbA1c était croissante de (20-30 ans) à (> 70 ans) respectivement de 5,46 à 5,94 %. Il n'y avait pas de différence statistiquement significative entre les deux sexes pour les témoins et les malades. Chez les diabétiques, une élévation de 1 % de l'HbA1c correspondrait à une élévation de 18 mg/dL pour G0. Conclusion: Il est important pour les cliniciens de connaître l'intervalle de référence correspondant à leur patient afin de mieux interpréter un diabète chez un sujet présentant une G0 normale. La corrélation G0/HbA1c permettrait un meilleur contrôle de l'équilibre glycémique. © 2010 Elsevier Masson SAS.
PubMed | Service de biochimie clinique and University Paris Diderot
Type: Journal Article | Journal: Annales de biologie clinique | Year: 2016
Inflammatory bowel diseases are chronic diseases that result from an inflammation of the intestinal wall. They are suspected in any patient presenting with intestinal symptoms. Until recently, diagnosis was mainly based both on clinical and endoscopic arguments. The use of an easy, fast, reliable, non-invasive and inexpensive test must not only assist in the diagnosis but also contribute to their evolutionary and therapeutic monitoring. To date, fecal calprotectin is the most documented in this perspective. This marker allows to discriminate between functional and organic bowel processes with good sensitivity and good specificity. The determination of the fecal calprotectin level in stools contributes to the evaluation of the degree of disease activity and monitoring of therapeutic response.
PubMed | Besancon University Hospital Center, Laboratoire Of Biochimie Et Of Biologie Moleculaire, CMRR, Center Memoire Of Recherches Et Of Ressource and 6 more.
Type: | Journal: La Revue de medecine interne | Year: 2016
The role of biomarkers in clinical research was recently highlighted in the new criteria for the diagnosis of Alzheimers disease. Cerebro-spinal fluid (CSF) biomarkers (total Tau protein, threonine 181phosphorylated Tau protein and amyloid A1-42peptide) are associated with cerebral neuropathological lesions observed in Alzheimers disease (neuronal death, neurofibrillary tangle with abnormal Tau deposits and amyloid plaque). A1-40amyloid peptide dosage helps to interpret A1-42results. As suggested in the latest international criteria and the French HAS (Haute Autorit de sant) recommendations, using theses CSF biomarkers should not be systematic but sometimes could be performed to improve confidence about the diagnostic of Alzheimers disease in young subjects or in complex clinical situations. Future biomarkers actually in development will additionally help in diagnostic process (differential diagnosis) and in prognostic evaluation of neurodegenerative diseases.
PubMed | Service de Biochimie Clinique, Laboratoire Of Recherche Immuno Rhumatologie and University of Sousse
Type: Journal Article | Journal: The Journal of sports medicine and physical fitness | Year: 2016
The present study was designed to examine the influence of extreme impact loading induced by jump training on bone mineral density (BMD) and bone mineral content (BMC) in high level jumpers.Forty boys volunteered for the study aged 20 to 21 years. They were 22 high level jumpers and 18 controls. Bone mass and body composition measurements were performed by dual-energy X-ray absorptiometry, in the total body and at different sites.The results showed that BMC, BMD, bone area, and lean mass (P<0.0001) were significantly higher in the jumpers compared to the controls. A strong positive correlation was found between lean mass and bone parameters (BMC at the right femur, r=0.80; P<0.01). The values of the same correlation were weak in the control group. In addition, the effects of the regular practice of jumping on the BMD, BMC, and bone area were more pronounced in the lower limbs (P<0.01). These adaptations were site-specific, with increased bone mass at the lower limbs (P<0.01), especially at the legs, right and left leg (LRL) (P<0.05). It appears that the time dedicated to this activity may be account for the difference between jumpers and controls.The practice of high level jump starting at pubertal age generates an increase and an acquisition of the bone mass in males. This adaptation is further enhanced by the times dedicated for this activity. Therefore, it would be interesting to program jumping activities daily to conserve bone mineral and to prevent osteopenia.